Ma Yinglong announced that the subsidiary Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for azastine hydrochloride eye drops approved and issued by the State Drug Administration. The specification is 0.05%. It is managed as a Class A non-prescription drug, and the approval number is valid until July 7, 2031. The drug is suitable for treating itchy eyes caused by allergic conjunctivitis. In 2025, domestic market sales reached 154 million yuan, and the company invested 7.6621 million yuan in R&D. The approval helped to enrich the company's ophthalmology product line, but there is uncertainty about drug production and marketing.

Ma Yinglong announced that the subsidiary Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for azastine hydrochloride eye drops approved and issued by the State Drug Administration. The specification is 0.05%. It is managed as a Class A non-prescription drug, and the approval number is valid until July 7, 2031. The drug is suitable for treating itchy eyes caused by allergic conjunctivitis. In 2025, domestic market sales reached 154 million yuan, and the company invested 7.6621 million yuan in R&D. The approval helped to enrich the company's ophthalmology product line, but there is uncertainty about drug production and marketing.